"Vollmer TL"[Author] - Search Results

Year	Number of Results
1984	1
1987	1
1991	1
1992	1
1993	3
1994	2
1995	2
1999	1
2000	1
2001	1
2002	1
2004	3
2005	4
2006	3
2007	5
2008	5
2009	2
2010	4
2011	5
2012	1
2013	5
2014	3
2015	1
2016	2
2017	2
2018	1
2019	2
2020	4
2021	3

1

To PLEX or not to PLEX in natalizumab-associated PML.

Tyler KL, Vollmer TL. Tyler KL, et al. Among authors: vollmer tl. Neurology. 2017 Mar 21;88(12):1108-1109. doi: 10.1212/WNL.0000000000003747. Epub 2017 Feb 22. Neurology. 2017. PMID: 28228561 No abstract available.

2

A review of cases of neuromyelitis optica.

Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL. Bomprezzi R, et al. Among authors: vollmer tl. Neurologist. 2011 Mar;17(2):98-104. doi: 10.1097/NRL.0b013e31820a9d35. Neurologist. 2011. PMID: 21364364 Review.

3

Autoimmune encephalitis: A more treatable tragedy if diagnosed early.

Vollmer TL, McCarthy M. Vollmer TL, et al. Neurology. 2016 May 3;86(18):1655-6. doi: 10.1212/WNL.0000000000002641. Epub 2016 Apr 1. Neurology. 2016. PMID: 27037233 No abstract available.

4

Therapeutic decisions in multiple sclerosis: moving beyond efficacy.

Brück W, Gold R, Lund BT, Oreja-Guevara C, Prat A, Spencer CM, Steinman L, Tintoré M, Vollmer TL, Weber MS, Weiner LP, Ziemssen T, Zamvil SS. Brück W, et al. Among authors: vollmer tl. JAMA Neurol. 2013 Oct;70(10):1315-24. doi: 10.1001/jamaneurol.2013.3510. JAMA Neurol. 2013. PMID: 23921521 Free PMC article. Review.

5

Incorporating real-world clinical practice in multiple sclerosis economic evaluations.

McQueen RB, Nair KV, Vollmer TL, Campbell JD. McQueen RB, et al. Among authors: vollmer tl. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):869-72. doi: 10.1586/14737167.2015.1081060. Epub 2015 Aug 20. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 26295727

6

Ocular myasthenia: a protean disorder.

Weinberg DA, Lesser RL, Vollmer TL. Weinberg DA, et al. Among authors: vollmer tl. Surv Ophthalmol. 1994 Nov-Dec;39(3):169-210. doi: 10.1016/0039-6257(94)90194-5. Surv Ophthalmol. 1994. PMID: 7878520 Review.

7

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis.

Kuerten S, Jackson LJ, Kaye J, Vollmer TL. Kuerten S, et al. Among authors: vollmer tl. CNS Drugs. 2018 Nov;32(11):1039-1051. doi: 10.1007/s40263-018-0567-8. CNS Drugs. 2018. PMID: 30315499 Free PMC article. Review.

8

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate.

Honce JM, Nair KV, Hoyt BD, Seale RA, Sillau S, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Alvarez E. Honce JM, et al. Among authors: vollmer tl. Front Neurol. 2020 Sep 23;11:1045. doi: 10.3389/fneur.2020.01045. eCollection 2020. Front Neurol. 2020. PMID: 33071934 Free PMC article.

9

Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis.

Vollmer TL, Cohen JA, Alvarez E, Nair KV, Boster A, Katz J, Pardo G, Pei J, Raut P, Merchant S, MacLean E, Pradhan A, Moss B. Vollmer TL, et al. Mult Scler Relat Disord. 2020 Nov;46:102454. doi: 10.1016/j.msard.2020.102454. Epub 2020 Aug 18. Mult Scler Relat Disord. 2020. PMID: 33045496 Free article. Clinical Trial.

10

Validation of the functional assessment of chronic illness therapy - General treatment satisfaction (FACIT-TS-G) in multiple sclerosis.

Engebretson E, Seale RA, Valdez B, Vollmer TL, Medina LD. Engebretson E, et al. Among authors: vollmer tl. Mult Scler Relat Disord. 2020 Oct;45:102413. doi: 10.1016/j.msard.2020.102413. Epub 2020 Jul 18. Mult Scler Relat Disord. 2020. PMID: 32731202

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results